MTOR and Schnyder corneal dystrophy: Jagadeeswaran et al., 2017 [24] reported that two preclinical candidate drugs, the LSD1 inhibitor, RN-1, and the mammalian target of rapamycin (mTOR) inhibitor, sirolimus, both reduced mitochondrial-retaining RBCs in the SCD mouse model.